Long COVIDNUTRACOVIDNCT07397910
Clinical Trial on a Natural Compound to Improve Chronic Inflammation After SARS-CoV-2 Infection
A study testing Experimental Product, Physical exercise and No Physical Exercise in people with Long COVID, run by Universidad Católica San Antonio de Murcia at 1 site in Spain.
Trial summary
A controlled, randomized clinical trial is proposed to demonstrate the effectiveness of the experimental product in controlling hepato-pulmonary inflammation and neurovascular encephalic inflammation, which may constitute the etiopathogenic basis of persistent COVID. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Long COVID
- What is being tested?
- Experimental Product, Physical exercise and No Physical Exercise
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteSpain
- Study dates
- 23 Feb 2026to 3 Aug 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subjects of both sexes.
- Subjects over 18 and under 70 years of age who have had a SARS-CoV-2 infection diagnosed by PDIA.
- Subjects with a history of SARS-CoV-2 infection who, three months after the onset of COVID-19, continue to experience symptoms lasting at least two months that cannot be explained by another cause. These symptoms may be newly developed after initial recovery from an acute COVID-19 episode or persist from the initial illness.
- No history of sequelae from a severe acute illness.
Who cannot join
- Subjects with an underlying disease that explains the clinical manifestations.
- Presence of chronic inflammatory diseases.
- Subjects with acute infections.
- Evidence of active thromboembolic disorder, defined as those receiving parenteral anticoagulant or thrombolytic treatment.
- Excessive alcohol consumption.
- Hypersensitivity or intolerance to any of the components of the study products.
Show all 10Show fewer
- Use of any nutraceutical or dietary supplement.
- Severe or terminal illnesses.
- Subjects with a body mass index (BMI) over 32.
- Pregnant or lactating women.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Spain1 site
UCAM HiTech, Sport & Health Innovation Hub
Murcia
Francisco Javier López Román, 968278157 ext. 157, jlroman@ucam.edu
About this study
Official title: Clinical Trial to Analyze the Effectiveness of a Natural Compound on Chronic Immune-mediated Inflammatory Status in Subjects Who Have Had SARS-CoV-2 Infection.
A controlled, randomized clinical trial is proposed to demonstrate the effectiveness of the experimental product in controlling hepato-pulmonary inflammation and neurovascular encephalic inflammation, which may constitute the etiopathogenic basis of persistent COVID. In addition, an individualized training program will be implemented for each participant in order to improve chronic symptoms and, consequently, their quality of life.
Read the detailed description
Randomized, placebo-controlled, double-blind clinical trial with four parallel arms based on the product consumed (placebo or experimental product) and the performance of physical exercise (exercise or no exercise), designed to analyze the effectiveness of the product under investigation in reducing chronic immune-mediated inflammatory status in subjects who have had SARS-CoV-2 infection and present persistent symptoms 3 months after the onset of the infectious process.
The efficacy of the experimental product, consumed over a period of 4 months, will be determined in terms of reducing chronic inflammation and improving the quality of life of people suffering from this condition.
Clinical manifestations and chronic symptoms, quality of life, response to the individualized physical exercise program, and product safety will be taken into account.
- Conditions
- Long COVID
- Being tested
- Experimental Product, Control placebo, Physical exercise, No Physical Exercise
- Keywords
- LongCOVID, Nutraceutical, Immune-inflammatory state, Exercise
- Medical subject headings
- Post-Acute COVID-19 Syndrome, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Experimental ProductDietary supplement
Supplement consisting of orange extract, apigenin, luteolin, yerba mate extract, grapefruit extract, and olive leaf extract.
Control placeboDietary supplement
Product with identical characteristics to the experimental product.
Physical exerciseOther
During the study, subjects will have to develop a training program. A multicomponent program will be carried out during the 4 months of product consumption. The sessions will last 60 minutes and will be held 2-3 times per week.
No Physical ExerciseOther
During the study, subjects will only consume the product assigned to them in the randomization.
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Subjects in this group will consume a placebo product (maltodextrin) with the same organoleptic characteristics as the investigational product. Receives: Dietary Supplement: Control placebo; Other: No Physical Exercise |
| Natural extract | Experimental | Subjects in this group will consume the investigational product (experimental product composed of a combination of six natural extracts: grapefruit extract, apigenin, orange extract, luteolin, yerba mate extract, and olive leaf extract). Receives: Dietary Supplement: Experimental Product; Other: No Physical Exercise |
| Physical exercise and consumption of experimental product | Experimental | During the study, subjects must consume the experimental product and also follow a training program. A multi-component program will be carried out during the 4 months of product consumption. Sessions will last 60 minutes and will be held 2-3 times per week. Receives: Dietary Supplement: Experimental Product; Other: Physical exercise |
| Physical exercise and consumption of placebo product | Placebo comparator | During the study, subjects must consume the placebo product and also follow a training program. A multi-component program will be carried out during the 4 months of product consumption. Sessions will last 60 minutes and will be held 2-3 times per week. Receives: Dietary Supplement: Control placebo; Other: Physical exercise |
What is being measured
The primary outcome is the main question the study is designed to answer.
Immunoinflammatory profile
Antibody assay for molecular biomarkers of the brain-liver-lung axis, blood-brain barrier, immunometabolic pathways, and immune-inflammatory and immuno-angiogenic cardiac remodeling.
Measured: Blood samples will be taken twice, once at baseline, at the beginning of the trial and once at the end after 120 days of product intake.
Secondary outcomes (16)
Clinical signs
The number of clinical manifestations, the type of manifestation, intensity according to the visual analog scale from 0 to 10, and duration of the symptomps. The clinical manifestations will be those felt by the subject.
Measured: It will be recorded twice, before starting the consumption of the product and before the end of consumption (120 days)
Short Form 12 Health Survey
Measured by SF-12 questionnaire. Scale 0-100%
Measured: It will be measured twice, once at baseline and at the end of the study after 120 days of consumption.
Sleep quality
Measured by Pittsburgh test
Measured: Progress will be measured after 120 days of consumption.
Sleep efficiency
Measured by accelerometry, with Actigraph wGT3X-BT
Measured: Progress will be measured after 120 days of consumption.
Fatigue
Measured with Fatigue Severity Scale (FSS). Rated on a 7-point Likert scale (1=strongly disagree, 7=strongly agree), a mean score of \(\ge 4\) typically indicates a moderate to high level of fatigue.
Measured: Progress will be measured after 120 days of consumption.
Dyspnea
It will be measured with Modified Medical Research Council (mMRC)
Measured: Progress will be measured after 120 days of consumption.
Depression
It will be measured with Beck Depression Inventory (BDI). Scores are calculated by adding up the responses to 21 items, with a range from 0 to 63, and scores are interpreted by severity levels: 0-13 (minimal), 14-19 (mild), 20-28 (moderate), and 29-63 (severe).
Measured: Progress will be measured after 120 days of consumption.
Anxiety
It will be measured with the State-Trait Anxiety Inventory (STAI). The STAI (State-Trait Anxiety Inventory) assesses transient (state) and stable (trait) anxiety using 40 items (20 per subscale) with a Likert-type score from 0 to 3. The total score per subscale ranges from 0 to 60, with higher scores indicating greater anxiety.
Measured: Progress will be measured after 120 days of consumption.
Hospital Anxiety and Depression
Measured with Hospital Anxiety and Depression Scale (HADS). It is a self-administered instrument with 14 items (7 for anxiety, 7 for depression) that is scored from 0 to 3, with a maximum total of 21 points per subscale. A score of 7 or less indicates normality, 8-10 indicates a borderline case, and 11 or above indicates a probable case of anxiety or depression.
Measured: Progress will be measured after 120 days of consumption.
Stress level
Perceived stress scale (PSS). Measures stress levels over the past month on a scale of 0 to 56. The higher the score, the greater the perceived stress. Typical interpretive ranges include low stress (0-13), moderate stress (14-26), and high stress (27-40+).
Measured: Progress will be measured after 120 days of consumption.
Cardiorespiratory fitness.
A submaximal test will be performed.
Measured: Progress will be measured after 120 days of consumption.
The Rate of Force Development
The Rate of Force Development (RFD) measures the speed at which the neuromuscular system generates maximum force in a short period of time (typically in the first 100-200 ms). It is a key indicator of explosive strength and power, vital in fast movements, jumps, sprints, and climbing.
Measured: Progress will be measured after 120 days of consumption.
Maximum Voluntary Isometric Contraction
Maximum Voluntary Isometric Contraction (MVIC) is the gold standard for measuring muscle strength, involving maximum contraction without joint movement (isometric). It is used to evaluate muscle activation using electromyography, comparing the percentage of effort against the muscle's maximum possible strength.
Measured: Progress will be measured after 120 days of consumption.
Body composition
It is a control variable. Measured by bioimpedance.
Measured: The test will be measured at baseline and after 16 weeks of consumption.
Liver safety variables
It is a blood test that measures the presence of some enzymes, proteins and bilirubin in the blood, with the aim of determining if there is any alteration in the liver. Enzyme GPT, GOT, Gamma GT, LDH, alkaline phosphatase and bilirubin (UI/L)
Measured: Hematological samples were taken before (day 0) and after consumption of the product (day 120) both in the control group and in the experimental group.
Adverse events
It will be evaluated only at the end of the study.
Measured: After 16 weeks of consumption.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Feb 2026
- Study start23 Feb 2026 (estimated)
- Primary completion6 Jul 2026 (estimated)
- Study completion3 Aug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Long COVIDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universidad Católica San Antonio de Murcia
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Francisco Javier López Román, Universidad Católica San Antonio de Murcia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07397910
- Sponsor's protocol ID
- UCAMCFE-00038
- Acronym
- NUTRACOVID
- Status last verified
- Feb 2026
- First submitted
- 25 Jan 2026
- Last updated
- 9 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Trial to Analyze the Effectiveness of a Natural Compound on Chronic Immune-mediated Inflammatory Status in Subjects Who Have Had SARS-CoV-2 Infection.
- ClinicalTrials.gov ID
- NCT07397910
- Acronym / sponsor ID
- NUTRACOVID / UCAMCFE-00038
- Conditions
- Long COVID
- Keywords
- LongCOVID, Nutraceutical, Immune-inflammatory state, Exercise
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Universidad Católica San Antonio de MurciaUniversity, hospital or other
- Study start
- 23 Feb 2026 (estimated)
- Primary completion
- 6 Jul 2026 (estimated)
- Study completion
- 3 Aug 2026 (estimated)
- First posted
- 9 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A controlled, randomized clinical trial is proposed to demonstrate the effectiveness of the experimental product in controlling hepato-pulmonary inflammation and neurovascular encephalic inflammation, which may constitute the etiopathogenic basis of persistent COVID. In addition, an individualized training program will be implemented for each participant in order to improve chronic symptoms and, consequently, their quality of life.
Detailed description
Randomized, placebo-controlled, double-blind clinical trial with four parallel arms based on the product consumed (placebo or experimental product) and the performance of physical exercise (exercise or no exercise), designed to analyze the effectiveness of the product under investigation in reducing chronic immune-mediated inflammatory status in subjects who have had SARS-CoV-2 infection and present persistent symptoms 3 months after the onset of the infectious process.
The efficacy of the experimental product, consumed over a period of 4 months, will be determined in terms of reducing chronic inflammation and improving the quality of life of people suffering from this condition.
Clinical manifestations and chronic symptoms, quality of life, response to the individualized physical exercise program, and product safety will be taken into account.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Dietary Supplement: Control placebo, Other: No Physical ExerciseSubjects in this group will consume a placebo product (maltodextrin) with the same organoleptic characteristics as the investigational product. |
| Natural extract | Experimental | Dietary Supplement: Experimental Product, Other: No Physical ExerciseSubjects in this group will consume the investigational product (experimental product composed of a combination of six natural extracts: grapefruit extract, apigenin, orange extract, luteolin, yerba mate extract, and olive leaf extract). |
| Physical exercise and consumption of experimental product | Experimental | Dietary Supplement: Experimental Product, Other: Physical exerciseDuring the study, subjects must consume the experimental product and also follow a training program. A multi-component program will be carried out during the 4 months of product consumption. Sessions will last 60 minutes and will be held 2-3 times per week. |
| Physical exercise and consumption of placebo product | Placebo comparator | Dietary Supplement: Control placebo, Other: Physical exerciseDuring the study, subjects must consume the placebo product and also follow a training program. A multi-component program will be carried out during the 4 months of product consumption. Sessions will last 60 minutes and will be held 2-3 times per week. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Subjects of both sexes.
- Subjects over 18 and under 70 years of age who have had a SARS-CoV-2 infection diagnosed by PDIA.
- Subjects with a history of SARS-CoV-2 infection who, three months after the onset of COVID-19, continue to experience symptoms lasting at least two months that cannot be explained by another cause. These symptoms may be newly developed after initial recovery from an acute COVID-19 episode or persist from the initial illness.
- No history of sequelae from a severe acute illness.
Key exclusion criteria (10 listed)
- Subjects with an underlying disease that explains the clinical manifestations.
- Presence of chronic inflammatory diseases.
- Subjects with acute infections.
- Evidence of active thromboembolic disorder, defined as those receiving parenteral anticoagulant or thrombolytic treatment.
- Excessive alcohol consumption.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Experimental ProductSupplement consisting of orange extract, apigenin, luteolin, yerba mate extract, grapefruit extract, and olive leaf extract. | Dietary supplement | Natural extract, Physical exercise and consumption of experimental product |
| Control placeboProduct with identical characteristics to the experimental product. | Dietary supplement | Physical exercise and consumption of placebo product, Placebo |
| Physical exerciseDuring the study, subjects will have to develop a training program. A multicomponent program will be carried out during the 4 months of product consumption. The sessions will last 60 minutes and will be held 2-3 times per week. | Other | Physical exercise and consumption of experimental product, Physical exercise and consumption of placebo product |
| No Physical ExerciseDuring the study, subjects will only consume the product assigned to them in the randomization. | Other | Natural extract, Placebo |
Primary outcome
Immunoinflammatory profile
Time frame: Blood samples will be taken twice, once at baseline, at the beginning of the trial and once at the end after 120 days of product intake.
Antibody assay for molecular biomarkers of the brain-liver-lung axis, blood-brain barrier, immunometabolic pathways, and immune-inflammatory and immuno-angiogenic cardiac remodeling.
16 secondary outcomes
Clinical signs
Time frame: It will be recorded twice, before starting the consumption of the product and before the end of consumption (120 days)
Short Form 12 Health Survey
Time frame: It will be measured twice, once at baseline and at the end of the study after 120 days of consumption.
Sleep quality
Time frame: Progress will be measured after 120 days of consumption.
Sleep efficiency
Time frame: Progress will be measured after 120 days of consumption.
Fatigue
Time frame: Progress will be measured after 120 days of consumption.
Dyspnea
Time frame: Progress will be measured after 120 days of consumption.
Depression
Time frame: Progress will be measured after 120 days of consumption.
Anxiety
Time frame: Progress will be measured after 120 days of consumption.
Hospital Anxiety and Depression
Time frame: Progress will be measured after 120 days of consumption.
Stress level
Time frame: Progress will be measured after 120 days of consumption.
Cardiorespiratory fitness.
Time frame: Progress will be measured after 120 days of consumption.
The Rate of Force Development
Time frame: Progress will be measured after 120 days of consumption.
Maximum Voluntary Isometric Contraction
Time frame: Progress will be measured after 120 days of consumption.
Body composition
Time frame: The test will be measured at baseline and after 16 weeks of consumption.
Liver safety variables
Time frame: Hematological samples were taken before (day 0) and after consumption of the product (day 120) both in the control group and in the experimental group.
Adverse events
Time frame: After 16 weeks of consumption.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Long COVID
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Recruiting
Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study
ME/CFS, Fibromyalgia (FM)
Not yet recruitingPhase 3
The Study of Brave-LC LDN Treatment Trial
Post-acute COVID-19 Syndrome
Active, not recruitingObservational study
Epigenetic Changes in Long COVID Patients
Long COVID-19 Syndrome, Long COVID Symptoms
Enrolling by invitationPhase 2
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2
Systemic Inflammation, Neuroinflammation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Experimental Product, Physical exercise and No Physical Exercise in people with Long COVID, run by Universidad Católica San Antonio de Murcia at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 9 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Francisco Javier López Román (968278157 ext. 157, jlroman@ucam.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Immunoinflammatory profile (time frame: Blood samples will be taken twice, once at baseline, at the beginning of the trial and once at the end after 120 days of product intake.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Feb 2026.